WO2005097798A1 - Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments - Google Patents

Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments Download PDF

Info

Publication number
WO2005097798A1
WO2005097798A1 PCT/EP2005/003474 EP2005003474W WO2005097798A1 WO 2005097798 A1 WO2005097798 A1 WO 2005097798A1 EP 2005003474 W EP2005003474 W EP 2005003474W WO 2005097798 A1 WO2005097798 A1 WO 2005097798A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
amino
alkyl
methyl
substituted
Prior art date
Application number
PCT/EP2005/003474
Other languages
German (de)
English (en)
Inventor
Matthias Eckhardt
Frank Himmelsbach
Elke Langkopf
Norbert Hauel
Mohammad Tadayyon
Leo Thomas
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004017739A external-priority patent/DE102004017739A1/de
Priority claimed from DE200410025552 external-priority patent/DE102004025552A1/de
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim International Gmbh
Priority to EP05716507A priority Critical patent/EP1740589A1/fr
Priority to CA002561210A priority patent/CA2561210A1/fr
Priority to JP2007506703A priority patent/JP2007531780A/ja
Publication of WO2005097798A1 publication Critical patent/WO2005097798A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to new substituted imidazo [4,5-d] pyridazin-4-ones and 2-amino-imidazo [4,5-c] pyridin-4-ones of the general formula
  • DPP-IV dipeptidyl peptidase-IV
  • the Production their use for the prevention or treatment of diseases or conditions which are associated with increased DPP-IV activity or which can be prevented or alleviated by reducing the DPP-IV activity, in particular of type I or type II diabetes mellitus, the a compound of the general formula (I) or a physiologically tolerable salt thereof medicament and method for the production thereof.
  • DPP-IV dipeptidyl peptidase-IV
  • WO 03/104229 discloses imidazo [4,5-d] pyridazin-4-one and imidazo [4,5-c] - pyridin-4-one, which are substituted in position 2 by cyclic groups.
  • R 1 is an arylmethyl or arylethyl group
  • an arylprop-2-enyl or heteroarylprop-2-enyl group in which the propenyl chain by 1 to 4 fluorine atoms or a cyan, C ⁇ . 3 -alkyloxy-carbonyl or nitro group can be substituted,
  • X is a nitrogen atom or a CR 5 group, where R 5 is a hydrogen atom or a C ⁇ _ 3 alkyl group,
  • R 2 is a hydrogen atom
  • R a is a C 3 - 7 cycloalkyl group in which one or two methylene groups independently of one another each through an oxygen or sulfur atom, through a -NH- or -N (C ⁇ _ 3 -alkyl) group or through a carbonyl, sulfinyl or sulfonyl group can be replaced, or a trifluoromethyl, aryl, heteroaryl, cyano, carboxy, C ⁇ . 3 -alkoxy-carbonyl-, aminocarbonyl-, C ⁇ _ 3 -alkylamino-carbonyl-, di- (C ⁇ .
  • a C 3 - 7 cycloalkyl group in which one or two methylene groups independently of one another each through an oxygen or sulfur atom, through a -NH or -N (C ⁇ - 3 alkyl) group, or through a carbonyl, sulfinyl or sulfonyl group can be replaced, or
  • R 3 is a C 5 optionally substituted by a C 3 alkyl group. 7- cycloalkenylmethyl group,
  • R is an amino group substituted by the radicals R lü and R, in which R 15 is a hydrogen atom, a C ⁇ . 6 -alkyl-, C 3 . 6 -cycloalkyl-, C 3 . 6- cycloalkyl-C 1 . 3 - alkyl, aryl or aryl -C 3 alkyl group and
  • R 16 is R 17 -C 2 . 3 -alkyl group, the C 2 . 3 -Alkylt.eil is straight-chain and can be substituted by 1 to 4 C ⁇ _ 3 alkyl groups, which may be the same or different, and wherein the C 2 - 3 alkyl group can be linked from position 2 with R 17 , and
  • R 17 represents an amino or C 3 alkylamino group
  • R 15 is defined as mentioned above and R 18 is a C 3 .io-cycloalkyl-C 2 -alkyl group substituted in the 1 position of the cycloalkyl radical by R 19 or a 1- or 2-position by an R 19 -C ⁇ - 2 alkyl group substituted C 3 . ⁇ 0 cycloalkyl group, where R 19 is an amino or C ⁇ . 3 -alkylamino group,
  • R 15 is as defined above and R 20 is a C 4 - or C 8 - ⁇ o-cycloalkyl group, in which a methylene group from position 3 of the C 4 - or C 8 - ⁇ o-cycloalkyl group by an -NH- group is replaced represents
  • R 15 and R 21 are independently defined as mentioned above and R 21 is a C 3 - 4 - substituted in the 2- or 3-position by an amino or C 3 alkyl alkyl group or Represents C 8 -o-cycloalkyl group, where the abovementioned radicals R 18 , R 20 and R 21 can be mono- or disubstituted by R b , where the substituents can be the same or different and R is a fluorine atom, a C 3 alkyl, trifluoromethyl or cyano -, Amino-, C ⁇ . 3 alkyl ⁇ amino, hydroxy or C ⁇ .
  • aryl groups mentioned in the definition of the abovementioned radicals are to be understood as meaning phenyl or naphthyl groups which can be mono-, di- or tri-substituted independently of one another by R h , where the substituents can be identical or different and R h is one Fluorine, chlorine, bromine or iodine atom, a trifluoromethyl, cyan, nitro, amino, aminocarbonyl, C ⁇ -3-alkoxy-carbonyl, aminosulfonyl, methylsulfonyl, acetylamino, methylsulfonylamino , C 1 -3- alkyl, cyclopropyl, ethenyl, ethinyl, morpholinyl, hydroxy, C ⁇ - 3 alkyloxy, difluoromethoxy or trifluoromethoxy group, and in which each hydrogen atom is additionally represented by a fluorine atom can be replaced
  • heteroaryl groups mentioned in the definition of the abovementioned radicals are to be understood as a pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group,
  • alkyl, alkenyl and alkynyl groups mentioned above can be straight-chain or branched
  • the carboxy groups mentioned in the definition of the abovementioned radicals can be replaced by a group which can be converted into a carboxy group in vivo or by a group which is negatively charged under physiological conditions,
  • amino and imino groups mentioned in the definition of the abovementioned radicals can be substituted by a radical which can be split off in vivo.
  • a radical which can be split off in vivo.
  • Such groups are described, for example, in WO 98/46576 and by N.M. Nielsen et al. in International Journal of Pharmaceutics 39, 75-85 (1987).
  • a group which can be converted into a carboxy group in vivo is, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol, in which the alcoholic part preferably contains a Ci- ⁇ - alkanoI, a phenyl-C ⁇ - 3 -alkanol, a C 3 .g- Cycloalkanol, where a C 5 . 8- Cycloalkanol additionally by one or two C- ⁇ . 3 alkyl groups can be substituted, a Cs-s-cycloalkanol in which a methylene group in the 3- or 4-position by an oxygen atom or by an optionally by a C ⁇ . 3 -alkyl, phenyl -CC.
  • R p a C ⁇ . 8 alkyl, C 5 - 7 cycloalkyl, C 8 8 alkyloxy, C 5 7 cycloalkyloxy, phenyl or phenyl C 3 alkyl group,
  • R q is a hydrogen atom, a C ⁇ . -Alkyl-, Cs- 7 -cycloalkyl or phenyl group and
  • R r is a hydrogen atom or a C ⁇ . Represent 3 alkyl group
  • an imino or amino group in vivo for example a hydroxyl group, an acyl group such as one optionally substituted by fluorine, chlorine, bromine or iodine atoms, by C 3 alkyl or C 1-4 alkoxy groups mono- or disubstituted Phenylcarbonyl group, where the substituents can be the same or different, a pyridinoyl group or a C ⁇ _ ⁇ 6 alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl group, a C ⁇ .
  • an imino or amino group in vivo for example a hydroxyl group, an acyl group such as one optionally substituted by fluorine, chlorine, bromine or iodine atoms, by C 3 alkyl or C 1-4 alkoxy
  • R s CRt (R s CRt) -O-CO- or C ⁇ . 6 -alkyl-CO-O- (R s CRt) - (RsCRt) -O-CO group, in which R p to R r are defined as mentioned above,
  • R s and Rt which may be the same or different, represent hydrogen atoms or C 3 alkyl groups
  • saturated alkyl and alkoxy parts which contain more than 2 carbon atoms and, unless otherwise stated, mentioned in the definitions above and below also include their branched isomers such as the isopropyl, tert-butyl, isobutyl group etc. ,
  • R 1 comes for example the meaning of a 2-cyanobenzyl, 3-fluorobenzyl, 3-methoxybenzyl, 4-bromo-2-cyanobenzyl, 3-chloro-2-cyanobenzyl, 2-cyan-4-fluorobenzyl, 3.5 -Dimethoxybenzyl-, 2,6-dicyanbenzyl-, 5-cyanfuranylmethyl-, oxazolylmethyl-, isoxazolylmethyl-, 5-methoxycarbonylthienylmethyl-, pyridinylmethyl-, 3-cyanopyridine- 2-ylmethyl-, 6-cyanopyridin-2-ylmethyl-, 6-fluoropyridin-2-ylmethyl-, 3- (2-cyanophenyl) prop-2-enyl-, 3- (pyridin-2-yl) prop- 2-enyl-, 3- (pentafluorophenyl) prop-2-enyl-, phenylcarbonylmethyl-, 3-methoxyphenylcarbony
  • R 2 is, for example, the meaning of a hydrogen atom, a methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, 2-methylpropyl, tert-butyl, cyclopropyl, cyclobutyl, Cyclopentyl, cyclohexyl, 2-propen-1-yl, 2-propyn-1-yl, cyclopropylmethyl, phenyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-hydroxyethyl, 2-methoxyethyl, 2-ethoxyethyl, 2- (dimethylamino) ethyl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl, piperazin-1-yl, carboxy, methoxycarbonyl -, ethoxycarbonyl, carboxymethyl, (methoxycarbonyl) methyl, aminocarbonyl,
  • R 3 for example, the meaning of 2-propen-1-yl, 2-methyl-2-propen-1-yl, 1-buten-1-yl, 2-buten-1-yl, 3- Buten-1-yl, 2-methyl-2-buten-1-yl, 3-methyl-2-buten-1-yl, 2,3-dimethyl-2-buten-1-yl, 3- Methyl-3-buten-1-yl-, 1-cyclopenten-1-ylmethyl-, (2-methyl-1-cyclopenten-1-yl) methyl-, 1-cyclohexen-1 -ylmethyl-, 2-propyne -1-yl-, 2-butyn-1-yl, 3-butyn-1-yl, 2-chlorobenzyl, 2-bromobenzyl, 2-iodobenzyl, 2-cyanobenzyl, 3-fluorobenzyl, 2-methoxybenzyl -, 2-furanylmethyl, 3-furanylmethyl, 2-thienylmethyl or 3-thienylmethyl group into
  • R 4 is, for example, the meaning of a (2-aminocyclopropyl) amino, N- (2-aminocyclopropyl) -N-methylamino, (2-aminocyclobutyl) amino, N- (2-aminocyclobutyl) -N -methyl-amino-, N- (3-aminocyclobutyl) -N-methyl-amino-, N- (2-aminoethyl) -N- methyl-amino-, N- (1-aminoprop-2-yl) -N-methyl-amino-, N- (2-aminopropyl) -N-methyl-amino-, N- (1-amino-2-methyl-prop-2-yl) -N-methyl-amino-, N- (2-aminopropyl) -N-methyl-amino-, N- (1-amino-2-methyl- prop-2-yl) -N-methylamino
  • Preferred compounds of the general formula I are those in which
  • R 1 and R 4 are defined as mentioned above,
  • X is a nitrogen atom or a -CH group
  • R 2 is a hydrogen atom, a Cu alkyl, C 3 - 6 cycloalkyl or phenyl group and
  • R 3 is a 1-buten-1-yl, 2-buten-1-yl, 2-butyn-1-yl, cyclopent-1-enylmethyl, furanylmethyl, thienylmethyl, chlorobenzyl, Bromobenzyl, iodobenzyl, methoxybenzyl or cyanbenzyl group,
  • R 1 is phenylmethyl, phenylcarbonylmethyl, phenylprop-2-enyl, pyridinylmethyl, pyrimidinylmethyl, naphthylmethyl, quinolinylmethyl, isoquinolinylmethyl, chinazolinylmethyl, quinoxalinylmethyl, naphthyridinylmethyl, or benzotriazole or two fluorine, chlorine, bromine atoms or one or two cyano, nitro, amino, C- ⁇ - 3 alkyl, C ⁇ - 3 alkyloxy and morpholinyl groups, where the substituents are the same or different .
  • X is a nitrogen atom or a -CH group
  • R is a hydrogen atom
  • R 3 is 1-buten-1-yl, 2-buten-1-yl, 2-butyn-1-yl, cyclopent-1-enylmethyl, furanylmethyl, thienylmethyl, chlorobenzyl, Bromobenzyl, iodobenzyl or cyanobenzyl group and
  • R 4 represents an N- (2-aminoethyl) -N-methyl-amino group in which the ethyl group can be substituted by 1 to 4 methyl groups
  • R 1 is an isoquinolinylmethyl, quinazolinylmethyl or benzyl group which can be substituted by a 'methyl or cyano group,
  • X is a nitrogen atom or a -CH group
  • R 2 is a hydrogen atom
  • R 3 is a 2-butyn-1-yl group
  • R 4 is an N- (2-aminoethyl) -N-methylamino, N- (2-aminopropyl) -N-methylamino or N- (2-amino-2-methylpropyI) -N-methylamino group mean,
  • the compounds of the general formula I are obtained by processes known per se, for example by the following processes:
  • R 1 to R 3 and X are defined as mentioned at the outset and Z represents a leaving group such as a halogen atom, a substituted hydroxyl, mercapto, sulfinyl, sulfonyl or sulfonyloxy group such as a chlorine or bromine atom, a methanesulfonyl or methanesulfonyloxy group R 4 -H or salts thereof, where R 4 is as defined in the introduction.
  • Z represents a leaving group such as a halogen atom, a substituted hydroxyl, mercapto, sulfinyl, sulfonyl or sulfonyloxy group such as a chlorine or bromine atom, a methanesulfonyl or methanesulfonyloxy group R 4 -H or salts thereof, where R 4 is as defined in the introduction.
  • the reaction is advantageously carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide, ethylene glycol monomethyl ether, ethylene glycol diethyl ether or sulfolane, optionally in the presence of an inorganic or tertiary organic base, for example sodium carbonate, potassium carbonate or potassium hydroxide, a tertiary organic base , for example triethylamine, or in the presence of N-ethyldiisopropylamine (Hünig base), these organic bases can also serve as solvents at the same time, and if appropriate in the presence of a reaction accelerator such as an alkali metal halide or a palladium-based catalyst at temperatures between - 20 and 180 ° C, but preferably at temperatures between -10 and 120 ° C.
  • a reaction accelerator such as an alkali metal halide or a palladium-based
  • Z 2 represents one of the groups mentioned at the outset for R 4 which contains an amino group which is not bonded directly to the imidazopyridazinone backbone and which is Boc-protected in Z 2 , where Boc stands for a tert-butyloxycarbonyl radical.
  • the tert-butyloxycarbonyl radical is preferably cleaved off by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with bromotrimethylsilane or iodotrimethylsilane, if appropriate using a solvent such as methylene chloride, ethyl acetate, dioxane, methanol, isopropanol or diethyl ether at temperatures between 0 and 80 ° C.
  • an acid such as trifluoroacetic acid or hydrochloric acid
  • bromotrimethylsilane or iodotrimethylsilane if appropriate using a solvent such as methylene chloride, ethyl acetate, dioxane, methanol, isopropanol or diethyl ether at temperatures between 0 and 80 ° C.
  • any reactive groups present such as amino, alkylamino or imino groups, can be protected during the reaction by customary protective groups, which are split off again after the reaction.
  • the formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and for the amino group also includes the phthalyl group.
  • the subsequent subsequent splitting off of a protective residue used takes place, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as sodium hydroxide or potassium hydroxide or aprotic, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.
  • an aqueous solvent e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water
  • an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid
  • an alkali base
  • a benzyl, methoxybenzyl or benzyloxycarbonyl radical is cleaved off, for example, hydrogenolytically, for example using hydrogen in the presence of a catalyst such as palladium / carbon in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 ° C, but preferably at room temperatures between 20 and 60 ° C, and at a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar.
  • a 2,4-dimethoxybenzyl radical is preferably cleaved in trifluoroacetic acid in the presence of anisole.
  • a tert-butyl or tert-butyloxycarbonyl radical is preferably cleaved off by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or diethyl ether.
  • a trifluoroacetyl radical is preferably split off by treatment with an acid such as hydrochloric acid, if appropriate in the presence of a solvent such as acetic acid at temperatures between 50 and 120 ° C. or by treatment with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 ° C.
  • a phthalyl radical is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene / water or dioxane at temperatures between 20 and 50 ° C.
  • the compounds of general formula I obtained can be separated into their enantiomers and / or diastereomers.
  • cis / trans mixtures can be separated into their ice and trans isomers, and compounds with at least one optically active carbon atom can be separated into their enantiomers.
  • the cis / trans mixtures obtained can be chromatographed into their cis and trans isomers, the compounds of general formula I obtained which occur in racemates, according to methods known per se (see Allinger NL and Eliel EL in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) in their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms on the basis of their physico-chemical differences according to methods known per se, for example by chromatography and / or fractionated crystallization, separate into their diastereomers, which, if they occur in racemic form, can then be separated into the enantiomers as mentioned above.
  • the enantiomers are separated preferably by column separation on chiral phases or by recrystallization from an optically active solvent or by reaction with an optically active substance which forms salts or derivatives, such as esters or amides, for example esters or amides, in particular acids and their activated derivatives or alcohols, and Separation of the diastereomeric salt mixture or derivative obtained in this way, for example on the basis of different solubilities, it being possible for the free antipodes to be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
  • an optically active substance which forms salts or derivatives, such as esters or amides, for example esters or amides, in particular acids and their activated derivatives or alcohols
  • optically active acids are, for example, the D and L forms of tartaric acid or dibenzoyl tartaric acid, di-op-toluoyl tartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid or quinic acid.
  • suitable optically active alcohol are (+) - or (-) - menthol and optically active acyl radicals in amides are, for example, (+) - or (-) - menthyloxycarbonyl.
  • the compounds of the formula I obtained can be converted into their salts, in particular for pharmaceutical use into their physiologically tolerable salts with inorganic or organic acids.
  • suitable acids for this purpose are hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
  • the new compounds of formula I thus obtained if they contain a carboxy group, can then, if desired, be converted into their salts with inorganic or organic bases, in particular for their pharmaceutical use into their physiologically tolerable salts.
  • Suitable bases are, for example, sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
  • the compounds of general formulas II and III used as starting materials are either known from the literature or can be obtained by processes known per se from the literature (see Examples I to XI).
  • the compounds of the general formula I according to the invention and their physiologically tolerable salts have valuable pharmacological properties, in particular an inhibitory action on the enzyme DPP-IV.
  • the cell extract was obtained from cells solubilized in a buffer (10 mM Tris HCl, 0.15 M NaCl, 0.04 tiu aprotinin, 0.5% Nonidet-P40, pH 8.0) by centrifugation at 35000 g for 30 minutes at 4 ° C (to remove cell debris) won.
  • a buffer (10 mM Tris HCl, 0.15 M NaCl, 0.04 tiu aprotinin, 0.5% Nonidet-P40, pH 8.0
  • the DPP-IV assay was carried out as follows:
  • AFC amido-4-trifluoromethylcoumarin
  • 20 ⁇ l assay buffer final concentrations 50 mM Tris HCl pH 7.8, 50 mM NaCl, 1% DMSO
  • the reaction was started by adding 30 ⁇ l solubilized Caco-2 protein (final concentration 0.14 ⁇ g protein per well).
  • the test substances to be checked were typically added pre-diluted in 20 ⁇ l, the assay buffer volume then being reduced accordingly.
  • the reaction was carried out at room temperature, the incubation period was 60 minutes.
  • the compounds prepared according to the invention are well tolerated, since no changes in the behavior of the animals could be observed, for example, after oral administration of 10 mg / kg of the compound of Example 1 to rats.
  • the compounds of general formula I according to the invention and their corresponding pharmaceutically acceptable salts are suitable for influencing all those conditions or diseases which can be influenced by inhibiting DPP-IV activity . It is therefore to be expected that the compounds according to the invention for the prevention or treatment of diseases or conditions such as type 1 and type 2 diabetes mellitus, diabetic complications (such as, for example, retinopathy, nephropathy or neuropathies), metabolic acidosis or ketosis, reactive hypoglycemia, insulin resistance , Metabolic syndrome, dyslipidemia of various origins, arthritis, atherosclerosis and related diseases, obesity, allograft transplantation and osteoporosis caused by calcitonin are suitable.
  • diseases or conditions such as type 1 and type 2 diabetes mellitus, diabetic complications (such as, for example, retinopathy, nephropathy or neuropathies), metabolic acidosis or ketosis, reactive hypoglycemia, insulin resistance , Metabolic syndrome, dyslipidemia of various origins, arthritis, atheros
  • these substances are suitable for preventing B cell degeneration such as apoptosis or necrosis of pancreatic B cells.
  • the substances are further suitable for improving or restoring the functionality of pancreatic cells, in addition to increasing the number and size of pancreatic B cells.
  • the compounds according to the invention are suitable for achieving, among other things, a sedative or anxiolytic effect , to be able to influence catabolic conditions after operations or hormonal stress responses favorably or to reduce mortality and morbidity after myocardial infarction.
  • the compounds according to the invention are suitable for the treatment of all conditions which are related to the above-mentioned effects and are mediated by GLP-1 or GLP-2.
  • the compounds according to the invention can also be used as diuretics or antihypertensives and are suitable for the prevention and treatment of acute kidney failure.
  • the compounds according to the invention can be used to treat inflammatory diseases of the respiratory tract. They are also suitable for the prevention and therapy of chronic inflammatory bowel diseases such as irritable bowel syndrome (IBS), Crohn's disease or ulcerative colitis as well as for pancreatitis.
  • IBS irritable bowel syndrome
  • Crohn's disease Crohn's disease
  • ulcerative colitis as well as for pancreatitis.
  • DPP-IV inhibitors and thus also the compounds according to the invention can be used to treat infertility or to improve fertility in humans or in the mammalian organism, in particular if the infertility in connection with an insulin resistance or with the poly- cystic ovarian syndrome.
  • these substances are suitable for influencing sperm motility and can therefore be used as contraceptives for use in men.
  • the substances are suitable for influencing growth hormone deficiency states that are associated with short stature, and can be used sensibly in all indications in which growth hormone can be used.
  • the compounds according to the invention are also suitable for the treatment of various autoimmune diseases such as, for example, rheumatoid arthritis, multiple sclerosis, thyroid disease and Graves' disease, etc.
  • they can be used for viral diseases such as HIV infections, for stimulating blood formation, for benign prostatic hyperplasia, for gingivitis as well as for the treatment of neuronal defects and neurodegenerative diseases such as Alzheimer's disease.
  • Compounds described can also be used for the therapy of tumors, in particular for changing tumor invasion, as well as metastatisation. Examples here are the use in T-cell lymphomas, acute lymphoblastic leukemia, cell-based thyroid carcinomas, basal cell carcinomas or breast carcinomas.
  • indications are stroke, ischemia of various origins, Parkinson's disease and migraines.
  • further areas of indication include follicular and epidermal hyperkeratosis, increased keratinocyte proliferation, psoriasis, encephalomyelitis, glomerulonephritis, lipodystrophy and psychosomatic, depressive and neuropsychiatric diseases of various origins.
  • the compounds according to the invention can also be used in combination with other active ingredients.
  • Therapeutics suitable for such a combination include, for example, antidiabetic agents such as metformin, sulfonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinedione (e.g. rosiglitazone, pioglitazone), PPAR-gamma agonists (e.g.
  • Gl 262570 and antagonists, PPAR-gamma / alpha modulators (eg KRP 297), alpha-glucose inhibitors (eg acarbose, Voglibose), other DPPIV inhibitors, alpha2-antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin.
  • SGLT2 inhibitors such as T-1095 or KGT-1251 (869682), inhibitors of protein tyrosine phosphatase 1, substances which influence deregulated glucose production in the liver, such as inhibitors of glucose-6-phosphatase, or fructose-1, 6- bisphosphatase, the glycogen phosphorylase, glucagon receptor antagonists and inhibitors of the phosphoenolpyruvate carboxykinase, the glycogen synthase kinase or the pyruvate dehydrokinase, lipid-lowering agents such as HMG-CoA reductase inhibitor (e.g.
  • simvastatin deribibrate, fennafate, forafate (eg -alpha agonists, PPAR-delta agonists, ACAT inhibitors (eg Avasimibe) or cholesterol absorption inhibitors such as ezetimibe, bile acid binding substances such as for example colestyramine, inhibitors of ileal bile acid transport, HDL-increasing compounds such as, for example, inhibitors of CETP or regulators of ABC1 or active substances for the treatment of obesitas, such as sibutramine or tetrahydrolipstatin, dexfenfluramine, axokines, antagonists of the cannbinoidl receptor, MCH Receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or ß 3 agonists such as SB-418790 or AD-9677 as well as agonists of the 5HT2c receptor.
  • fennafate eg
  • a combination with drugs to influence high blood pressure such as All antagonists or ACE inhibitors, diuretics, ⁇ -blockers, Ca antagonists and others or combinations thereof are suitable.
  • the dosage required to achieve a corresponding effect is expediently 1 to 100 mg, preferably 1 to 30 mg for intravenous administration, and 1 to 1000 mg, preferably 1 to 100 mg, in each case 1 to 4 times a day for oral administration.
  • the compounds of formula I prepared according to the invention optionally in combination with other active substances, together with one or more inert customary carriers and / or diluents, e.g.
  • Example VIII Methyl 2-bromo-5- (frans-2-methoxy-vinyl) -3H-imidazole-4-carboxylate Under an argon atmosphere, 38 ml of 38 ml of an ice-cooled solution of 6.64 g of methoxy-methyltriphenylphosphonium chloride in 140 ml of tetrahydrofuran a 0.5 M solution of potassium bis (trimethylsilyl) amide in toluene was added dropwise over 10 min. The reaction mixture is stirred for a further 15 min in an ice bath and then cooled to -70 ° C.
  • dichloromethane is added give and make the solution alkaline with sodium hydroxide solution.
  • the organic phase is separated off and the aqueous phase is extracted twice with dichloromethane.
  • the combined organic phases are dried over sodium sulfate, the solvent is removed and the residue is purified on silica gel (dichloromethane / methanol 99: 1-
  • Product (2) was obtained by reacting a 1: 1 mixture of 2-bromo-3- (2-butyn-1-yl) -5 - [(3-methyl-isoquinolin-1-yl) methyl] -3.5 -dihydro-imidazo [4,5-c] pyridin-4-one and 2-
  • 1 coated tablet contains: active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropylmethyl cellulose 15.0 mg magnesium stearate 1.5 m ⁇ 230.0 mg
  • the active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethyl cellulose and half of the stated amount of magnesium stearate. Pressings with a diameter of approx. 13 mm are produced on a tabletting machine, these are rubbed on a suitable machine through a sieve with a 1.5 mm mesh size and mixed with the remaining amount of magnesium stearate. This granulate is pressed on a tablet machine into tablets of the desired shape. Core weight: 230 mg stamp: 9 mm, curved The dragee cores thus produced are coated with a film consisting essentially of hydroxypropylmethyl cellulose. The finished film coated tablets are polished with beeswax. Drage weight: 245 mg.
  • Composition 1 tablet contains: Active substance 100.0 mg milk sugar 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mg 220.0 mg
  • 1 tablet contains: active substance 150.0 mg milk sugar powder 89.0 mg corn starch 40.0 mg colloids silica 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg 300.0 mg
  • the active substance mixed with milk sugar, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a sieve with a 1.5 mm mesh size.
  • 1 capsule contains: Active ingredient 150.0 mg corn starch dr. approx. 180.0 mg powdered milk sugar approx. 87.0 mg magnesium stearate 3.0 mg approx. 420.0 mg
  • the active ingredient is mixed with the excipients, passed through a sieve with a mesh size of 0.75 mm and mixed homogeneously in a suitable device.
  • the final mix is filled into size 1 hard gelatin capsules.
  • 1 suppository contains: Active ingredient 150.0 mg polyethylene glycol 1500 550.0 mg polyethylene glycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 2000.0 mg
  • 100 ml suspension contain: Active ingredient 1.00 g carboxymethyl cellulose Na salt 0.10 g p-hydroxybenzoic acid methyl ester 0.05 g p-hydroxybenzoic acid propyl ester 0.01 g cane sugar 10.00 g glycerin 5.00 g sorbitol solution 70% 20.00 g aroma 0.30 g water dist. ad 100 ml
  • Dest. Water is heated to 70 ° C. P-Hydroxybenzoic acid methyl ester and propyl ester as well as glycerol and carboxymethyl cellulose sodium salt are dissolved therein with stirring. It is cooled to room temperature and the active ingredient is added with stirring and dispersed homogeneously. After adding and dissolving the sugar, the sorbitol solution and the aroma, the suspension is evacuated with stirring for deaeration. 5 ml of suspension contain 50 mg of active ingredient.
  • composition active ingredient 10.0 mg 0.01 n hydrochloric acid s.q. Aqua bidest ad 2.0 ml
  • the active substance is dissolved in the required amount of 0.01N HCl, made isotonic with sodium chloride, sterile filtered and filled into 2 ml ampoules.
  • composition active ingredient 50.0 mg 0.01 N hydrochloric acid s.q. Aqua bidest to 10.0 ml
  • the active substance is dissolved in the required amount of 0.01N HCl, made isotonic with sodium chloride, sterile filtered and filled into 10 ml ampoules.

Abstract

La présente invention concerne des 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones de formule générale (I), dans laquelle R1 à R4 et X sont tels que définis dans les revendications 1 à 6, leurs tautomères, leurs énantiomères, leurs diastéréomères, leurs mélanges et leurs sels, lesquels composés présentent de précieuses propriétés pharmacologiques, en particulier un effet inhibiteur sur l'activité de l'enzyme dipeptidylpeptidase-IV (DPP-IV).
PCT/EP2005/003474 2004-04-10 2005-04-02 Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments WO2005097798A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05716507A EP1740589A1 (fr) 2004-04-10 2005-04-02 Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments
CA002561210A CA2561210A1 (fr) 2004-04-10 2005-04-02 Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments
JP2007506703A JP2007531780A (ja) 2004-04-10 2005-04-02 新規な２−アミノ−イミダゾ［４，５−ｄ］ピリダジン−４−オン及び２−アミノ−イミダゾ［４，５−ｃ］ピリダジン−４−オン、その製法及び医薬としての使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004017739.2 2004-04-10
DE102004017739A DE102004017739A1 (de) 2004-04-10 2004-04-10 Neue 2-Amino-imidazo(4,5-d)pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE200410025552 DE102004025552A1 (de) 2004-05-25 2004-05-25 Neue 2-Amino-imidazo[4,5-d]pyridazin-4-one und 2-Amino-imidazo[4,5-c]pyridin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE102004025552.0 2004-05-25

Publications (1)

Publication Number Publication Date
WO2005097798A1 true WO2005097798A1 (fr) 2005-10-20

Family

ID=34964126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003474 WO2005097798A1 (fr) 2004-04-10 2005-04-02 Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments

Country Status (4)

Country Link
EP (1) EP1740589A1 (fr)
JP (1) JP2007531780A (fr)
CA (1) CA2561210A1 (fr)
WO (1) WO2005097798A1 (fr)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072083A1 (fr) 2005-12-23 2007-06-28 Prosidion Limited Traitement du diabete de type 2 par combinaison d'un inhibiteur de dpiv a de la metformine ou de la thiazolidinedione
WO2009022007A1 (fr) 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique comprenant un dérivé de benzène à substitution glucopyranosyle
WO2009024542A2 (fr) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Utilisation de dérivés de la purine
WO2010072776A1 (fr) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Formes de sel d'un composé organique
WO2010079197A1 (fr) 2009-01-07 2010-07-15 Boehringer Ingelheim International Gmbh Traitement du diabète chez des patients avec une régulation inadéquate de la glycémie malgré une thérapie par la metformine comprenant un inhibiteur de dpp-iv
WO2010086411A1 (fr) 2009-01-29 2010-08-05 Boehringer Ingelheim International Gmbh Traitement du diabète chez des patients pédiatriques
WO2010092163A2 (fr) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Médicaments antidiabétiques
WO2010092125A1 (fr) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp-iv et facultativement un autre agent antidiabétique et ses utilisations
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US7906539B2 (en) 2004-06-24 2011-03-15 Boehringer Ingelheim International Gmbh Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
WO2011039367A2 (fr) 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Utilisations thérapeutiques de compositions pharmaceutiques
WO2011064352A1 (fr) 2009-11-27 2011-06-03 Boehringer Ingelheim International Gmbh Traitement de patients diabétiques génotypés par des inhibiteurs de dpp-iv tels que la linagliptine
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
WO2011138421A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combinaison thérapeutique
WO2011138380A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques comprenant de la pioglitazone et de la linagliptine
WO2011161161A1 (fr) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Thérapie du diabète
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2012065993A1 (fr) 2010-11-15 2012-05-24 Boehringer Ingelheim International Gmbh Thérapie antidiabétique vasoprotectrice et cardioprotectrice
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
WO2013098372A1 (fr) 2011-12-29 2013-07-04 Boehringer Ingelheim International Gmbh Utilisation thérapeutique sous-cutanée d'un inhibiteur de dpp-4
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
WO2013171166A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de sirs et/ou d'une sepsie
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2013174768A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans le traitement du diabète auto-immun, notamment du lada
WO2014045266A1 (fr) 2012-09-24 2014-03-27 Ulf Eriksson Traitement de diabète de type 2 et d'états apparentés
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2018104263A1 (fr) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'amélioration de l'activité de médicaments à base d'incrétine chez des sujets en ayant besoin
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
EP3626238A1 (fr) 2008-08-15 2020-03-25 Boehringer Ingelheim International GmbH Inhibiteurs de dpp-4 destinés à l'utilisation dans la cicatrisation des lésions des diabétiques
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004022970A1 (de) * 2004-05-10 2005-12-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046576A2 (fr) 1997-04-15 1998-10-22 Genentech, Inc. Promedicaments haloalcoxycarbonyles
WO2003104229A1 (fr) 2002-06-06 2003-12-18 エーザイ株式会社 Nouveau derive d'imidazole fondu
WO2004050658A1 (fr) * 2002-12-03 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouvelles imidazo-pyridinones et imidazo-pyridazinones substituees, leur production et leur utilisation en tant que medicaments
WO2004111051A1 (fr) * 2003-06-18 2004-12-23 Boehringer Ingelheim International Gmbh Derives d'imidazopyridazinones et d'imidazopyridones, leur preparation et leur utilisation comme medicaments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1953162T3 (da) * 2001-02-24 2012-09-10 Boehringer Ingelheim Pharma Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel.
EP1557165A4 (fr) * 2002-09-26 2008-12-03 Eisai R&D Man Co Ltd Medicament combine
DE102004012366A1 (de) * 2004-03-13 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Imidazopyridazindione, deren Herstellung und deren Verwendung als Arzneimittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046576A2 (fr) 1997-04-15 1998-10-22 Genentech, Inc. Promedicaments haloalcoxycarbonyles
WO2003104229A1 (fr) 2002-06-06 2003-12-18 エーザイ株式会社 Nouveau derive d'imidazole fondu
WO2004050658A1 (fr) * 2002-12-03 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouvelles imidazo-pyridinones et imidazo-pyridazinones substituees, leur production et leur utilisation en tant que medicaments
WO2004111051A1 (fr) * 2003-06-18 2004-12-23 Boehringer Ingelheim International Gmbh Derives d'imidazopyridazinones et d'imidazopyridones, leur preparation et leur utilisation comme medicaments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLINGER N. L.; ELIEL E. L.: "Topics in Stereochemistry", vol. 6, 1971, WILEY INTERSCIENCE
N.M. NIELSEN ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 39, 1987, pages 75 - 85
REIHER ET AL.: "Increased expression of intestinal cell line Caco-2", PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 5757 - 5761

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US8178541B2 (en) 2002-08-21 2012-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7906539B2 (en) 2004-06-24 2011-03-15 Boehringer Ingelheim International Gmbh Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8541450B2 (en) 2004-11-05 2013-09-24 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
WO2007072083A1 (fr) 2005-12-23 2007-06-28 Prosidion Limited Traitement du diabete de type 2 par combinaison d'un inhibiteur de dpiv a de la metformine ou de la thiazolidinedione
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
EP2698152A1 (fr) 2007-08-16 2014-02-19 Boehringer Ingelheim International GmbH Composition pharmaceutique comprenant un dérivé de benzène substitué de glucopyranosyl
EP3939577A1 (fr) 2007-08-16 2022-01-19 Boehringer Ingelheim International GmbH Composition pharmaceutique comprenant un dérivé de benzène substitué par glucopyranosyle
WO2009022007A1 (fr) 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique comprenant un dérivé de benzène à substitution glucopyranosyle
EP3542801A1 (fr) 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Dérivés de la purine destinés à être utilisés dans le traitement de maladies associées à fab
WO2009024542A3 (fr) * 2007-08-17 2009-05-22 Boehringer Ingelheim Int Utilisation de dérivés de la purine
EP2190434B1 (fr) 2007-08-17 2019-04-17 Boehringer Ingelheim International GmbH Utilisation de derives de la purine pour leur utilisation dans le traitement des maladies liees a fap
JP2010536820A (ja) * 2007-08-17 2010-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆａｂ関連疾患治療用プリン誘導体
WO2009024542A2 (fr) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Utilisation de dérivés de la purine
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
EP2990037A1 (fr) 2008-08-06 2016-03-02 Boehringer Ingelheim International GmbH Traitement du diabète chez les patients non appropriés pour la thérapie au metformine
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
EP3598974A1 (fr) 2008-08-06 2020-01-29 Boehringer Ingelheim International GmbH Traitement du diabète chez les patients non appropriés pour la thérapie au metformine
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
EP3626238A1 (fr) 2008-08-15 2020-03-25 Boehringer Ingelheim International GmbH Inhibiteurs de dpp-4 destinés à l'utilisation dans la cicatrisation des lésions des diabétiques
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
WO2010072776A1 (fr) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Formes de sel d'un composé organique
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
WO2010079197A1 (fr) 2009-01-07 2010-07-15 Boehringer Ingelheim International Gmbh Traitement du diabète chez des patients avec une régulation inadéquate de la glycémie malgré une thérapie par la metformine comprenant un inhibiteur de dpp-iv
WO2010086411A1 (fr) 2009-01-29 2010-08-05 Boehringer Ingelheim International Gmbh Traitement du diabète chez des patients pédiatriques
WO2010092125A1 (fr) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp-iv et facultativement un autre agent antidiabétique et ses utilisations
WO2010092163A2 (fr) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Médicaments antidiabétiques
WO2011039367A2 (fr) 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Utilisations thérapeutiques de compositions pharmaceutiques
EP4209210A1 (fr) 2009-10-02 2023-07-12 Boehringer Ingelheim International GmbH Compositions pharmaceutiques comprenant bi-1356 et metformine
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
EP3646859A1 (fr) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Traitement de patients diabétiques génotypés avec des inhibiteurs de dpp-iv tels que la linagliptine
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011064352A1 (fr) 2009-11-27 2011-06-03 Boehringer Ingelheim International Gmbh Traitement de patients diabétiques génotypés par des inhibiteurs de dpp-iv tels que la linagliptine
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
WO2011138421A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combinaison thérapeutique
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
WO2011138380A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques comprenant de la pioglitazone et de la linagliptine
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011161161A1 (fr) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Thérapie du diabète
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
WO2012065993A1 (fr) 2010-11-15 2012-05-24 Boehringer Ingelheim International Gmbh Thérapie antidiabétique vasoprotectrice et cardioprotectrice
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013098372A1 (fr) 2011-12-29 2013-07-04 Boehringer Ingelheim International Gmbh Utilisation thérapeutique sous-cutanée d'un inhibiteur de dpp-4
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de sirs et/ou d'une sepsie
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174768A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans le traitement du diabète auto-immun, notamment du lada
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2014045266A1 (fr) 2012-09-24 2014-03-27 Ulf Eriksson Traitement de diabète de type 2 et d'états apparentés
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
WO2018104263A1 (fr) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'amélioration de l'activité de médicaments à base d'incrétine chez des sujets en ayant besoin

Also Published As

Publication number Publication date
EP1740589A1 (fr) 2007-01-10
JP2007531780A (ja) 2007-11-08
CA2561210A1 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
EP1740589A1 (fr) Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments
EP1709049B1 (fr) Composes imidazol bicycliques, leur fabrication et leur utilisation comme medicaments
EP1761517B1 (fr) Nouveaux imidazoles et triazoles, procede pour les produire et leur utilisation en tant que medicaments
EP1554278B1 (fr) Derives de xanthine, leur production et leur utilisation comme medicaments
EP1720875B1 (fr) 8-[ 3-amino-piperidin-1-yl]-xanthines, leur production et leur utilisation comme medicament
EP2119717B1 (fr) 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que complexe DDP IV
EP1791844A1 (fr) 8-(3-amino-piperidin-1-yl)-7-(but-2-inyl)-xanthines, leur production et leur utilisation en tant que medicaments
EP1689748B1 (fr) Nouvelle xanthine 8-(piperazine-1-yl) et 8-( 1,4 diazepan-1-yl), sa production et son utilisation comme medicament
EP1742949A1 (fr) Nouveaux 2-(piperazin-1-yle)-et 2-([1,4]diazepan-1-yle)-imidazo-[4,5-d]pyridazin-4-ones, leur preparation et utilisation comme médicaments pour le traitement de diabetes mellitus
DE102004044221A1 (de) Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1532150A1 (fr) Nouveaux derives de purine, leur procede de production et leur utilisation en tant que medicament
DE10109021A1 (de) Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1763530A1 (fr) Imidazopyridazindione, sa fabrication et son utilisation comme medicament
DE102004008112A1 (de) 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
DE102004017739A1 (de) Neue 2-Amino-imidazo(4,5-d)pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE102004025552A1 (de) Neue 2-Amino-imidazo[4,5-d]pyridazin-4-one und 2-Amino-imidazo[4,5-c]pyridin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE102004012921A1 (de) 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10309927A1 (de) Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE102004032263A1 (de) 8-[3-Amino-piperidin-1yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005716507

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2561210

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007506703

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005716507

Country of ref document: EP